A Biochemical Society Focused Meeting
Tumour cells rapidly evolve to acquire resistance to new, targeted therapeutics such as protein kinase inhibitors. Understanding such ‘acquired resistance’ has obvious clinical relevance but also reveals the plasticity of signalling pathways and their ability to remodel through feedback and cross-talk. This meeting will highlight advances in understanding how tumour cells adapt to inhibition of specific signalling pathways and the role this plays in acquired resistance.
- RAF-MEK-ERK signalling
- Tyrosine kinases and their inhibitors
- TOR/PI3K inhibitors
- Kinome reprogramming
- Cell survival/cell death signalling
- Systems and computational biology approaches
Proceedings (invited speakers) have been published in Biochemical Society Transactions.
Abstract submission is now closed.
If you wish to submit a late abstract please contact the conference office.
Earlybird registration deadline: 5 December 2013.
A Biochemical Society poster prize of £100 was awarded to the best poster.
The winner of the Biochemical Society poster prize:
Niraj Shah, University of Liverpool, United Kingdom -Regulation of miR-125b in acute myeloid leukaemia
Oral communication slots are available at this meeting. All attendees, particularly researchers in the early stages of their career, are invited to submit a poster abstract for consideration as an oral communication.
A Biochemical Society poster prize of £100 will be awarded to the best poster.
Student Bursaries are available for this meeting.
Not a member of the Biochemical Society? Join today and save up to £100 on your registration fee.